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Abstract
Background: Bisphosphonates (BPs) and other antiresorptive agents such as denosumab are widely prescribed 
for the treatment of osteoporosis and are also used in patients with multiple myeloma and metastatic breast or 
prostate cancer for avoiding bone reabsorption and fractures that result in increased morbidity-mortality among 
such individuals. 
Material and Methods: We made a bibliographic search to analyze the concept, diagnosis and the different clas-
sifications for  bisphosphonate-associated osteonecrosis of the jaws. 
Results: Osteonecrosis of the jaws (ONJ) is an important complication of exposure to BPs or other antiresorptive 
agents, and although its prevalence is low, it can pose management problems. The definition, diagnosis and clas-
sification of osteonecrosis have evolved since Marx reported the first cases in 2003. 
Conclusions: The present study offers a literature review and update on the existing diagnostic methods and clas-
sification of the disorder, with a view to facilitating earlier and more effective treatment.
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Introduction
Bisphosphonates (BPs) are stable pyrophosphate ana-
logs that modulate bone metabolism, and are generally 
used to treat certain diseases involving bone reabsorp-
tion, such as osteoporosis or Paget’s disease (usually 
administered via the oral route), or hypercalcemia as-
sociated to different malignancies such as multiple my-
eloma and bone metastases secondary to solid tumors of 
the breast or other locations (via the intravenous route). 
Bisphosphonates fundamentally act by inhibiting bone 
reabsorption, with the limitation of osteoclast acti
vity, though they are also considered to exert an an-
tiangiogenic effect (1,2). Other antiresorptive drugs 
apart from BPs are also used to treat osteoporosis, 
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multiple myeloma and bone metastases. In this regard, 
denosumab (a RANKL inhibitor) has been included 
in the treatment guides as an option for preventing 
bone problems (e.g., hip or vertebral fractures), and is 
administered via the subcutaneous route once every 
6 months for the ma-nagement of osteoporosis (1,3).
However, the use of both BPs and other antiresorp-
tive drugs can produce adverse effects in the form of 
gastrointestinal disorders or osteonecrosis of the jaws 
(ONJ). The latter is defined as an area of exposed or 
necrotic bone that fails to heal within 8 weeks in patients 
who have received treatment with BPs in the absence 
of maxillary radiotherapy (4). The pathogenesis of ONJ 
remains unclear, though the suppression of osteoclast-
mediated bone remodeling with consequent bone scle-
rosis and ischemia has been suggest as the likely causal 
mechanism. This moreover would explain the increased 
risk of ONJ when BPs are administered in combination 
with antiangiogenic agents such as bevacizumab or su-
nitinib (5).
- Frequency of appearance
BPs for the treatment of osteoporosis
The prevalence of ONJ is far greater in patients treated 
with intravenous BPs than in those who receive oral BPs; 
indeed, some authors consider the association between 
oral BPs and ONJ to be insignificant (6). As a result, the 
recommendations regarding dental treatment (e.g., sur-
gery or dental implant placement) in such patients can 
be vague and lack firm supporting evidence (6).
BPs via the oral route: The prevalence of ONJ var-
ies greatly (0.001-0.10%), depending on the literature 
source (7,8). With a treatment duration of four years 
or more, the reported prevalence is 0.21%, while the 
prevalence drops to 0.04% with shorter treatments (7). 
In a European multicenter study involving 470 cases of 
ONJ due to BPs, a total of 37 (7.8%) were attributed 
to oral BPs prescribed for the treatment of osteoporosis 
(6). The clinical significance of the oral route therefore 
should not be underestimated.
The incidence ranges from 1.04-69 cases per 100,000 
patients/year (8). Kühl et al. (9) recorded a mean inci-
dence of 0.12%, while other authors (10) have described 
incidences of between 0.0009%-0.034%.
Intravenous BPs for the treatment of osteoporosis: 
The ONJ prevalence in this case is greater, between 
0-0.348% (8). The incidence ranges from 0-90 cases per 
100,000 patients/year (8).
Intravenous BPs in cancer treatments
The prevalence of ONJ in cancer patients treated with 
intravenous BPs varies between 0.52-7.4%, depending 
on the source (3,5,11). The incidence in turn ranges 
from 0.8-12% (9,10). 
On comparing denosumab with BPs in cancer patients, 
the former drug has been found to offer a greater de-
crease in bone events and superior safety in patients 
with kidney disease. However, the associated ONJ rate 
is similar to that observed with BPs, and hypocalcemia 
is comparatively more frequent (12,13).
The systemic risk factors for ONJ are the type of BP 
used, the administration route, the duration of treat-
ment, the cumulative dose, the background disease for 
which the medication is prescribed, concomitant thera-
pies (e.g., chemotherapy, corticosteroids, antiangiogenic 
agents, etc.), patient habits (smoking, alcohol, etc.), gen-
der, age, genetic factors, and other disease conditions 
such as diabetes mellitus, rheumatoid arthritis, hemo-
dialysis, etc. (5,14).
The local risk factors in turn include dentoalveolar 
surgery (especially extractions) – this being the lead-
ing risk factor for ONJ in cancer patients subjected to 
antiresorptive treatment – as well as dental and peri-
odontal infection, and removable dentures. Anatomical 
factors (mandible, torus) also play a role (5,11,14).
The aim of this study is to offer an update on the con-
cept, diagnosis and classification of ONJ due to BPs.
Material and Methods
A literature search was made of the Medline-PubMed, 
Scopus and Cochrane databases, using the following 
key words: osteonecrosis, concept, diagnosis, classifi-
cation, bisphosphonates, staging, jaws. The key words 
were validated in the MeSH and were combined using 
the boolean operators AND / OR.
The inclusion criteria were: articles published in Eng-
lish or Spanish in the period between 2006-2015, human 
studies and reviews, systematic reviews, metaanalyses 
and consensus documents. In addition, a manual search 
was made of the references cited in key articles, includ-
ing relevant letters to the editor and case series. Articles 
centered on the etiopathogenesis and/or treatment of 
ONJ were not included.
A total of 675 articles were identified. Of these, 583 were 
excluded due to duplication and/or after evaluation of 
the title and abstract. A full-text evaluation was made of 
the remaining 92 articles, with the final exclusion of 66 
publications that were not considered to be sufficiently 
related to the aspects of ONJ which we aimed to analyze 
(Fig. 1).
Results
Of the 26 articles selected for the present review, most 
were published in the year 2009 (n = 8, 30.8%). The 
authors were from the United States or Canada in 13 
cases (50%), and from Europe (Spain, Italy, Denmark, 
United Kingdom) in 11 cases (42.3%). One publication 
was from Japan and one was an international consen-
sus document (United States, Canada, Germany, New 
Zealand, Japan, Italy, United Kingdom, Jordan, Aus-
tria, Denmark, Finland, Switzerland and Saudi Arabia). 
Ten articles addressed all three aspects reviewed in our 
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study (concept, diagnosis and treatment) (38.5%), while 
the rest addressed one or more of them. Of the total ar-
ticles selected, 8 were consensus documents, four were 
letters to the editor, four were case series, one was a 
case-control study, 5 were reviews, two were clinical 
cases, and two were retrospective studies (Table 1).
Discussion
- Concept and diagnosis
A number of terms have been used in reference to os-
teonecrosis of the jaws due to bisphosphonate exposure, 
including bisphosphonate-associated osteonecrosis of 
the jaws (BAONJ), bisphosphonate-related osteonecro-
sis of the jaws (BRONJ), bisphosphonate-induced os-
teonecrosis of the jaws (BIONJ), bisphosphonate-rela-
ted osteonecrosis (BRON), or simply bisphosphonate 
osteonecrosis (BON) (15). 
The first cases of ONJ due to BPs were published by 
Marx in 2003 (16), and since then there has been a 
growing number of articles on this subject (17). Since 
the year 2006 different societies and expert panels have 
proposed a number of clinical descriptions for defining 
this new disease entity (18). As an example, in 2006 
the American Dental Association (ADA) considered 
the typical clinical presentation of ONJ to include pain, 
swelling of the soft tissues, infection, tooth mobility, 
suppuration and bone exposure. Likewise in 2006, the 
Australia and New Zealand ONJ work group (19) under-
scored the lack of a clear definition of the disease. The 
authors suggested the definition of ONJ as an “area of 
exposed bone persisting for over 6 weeks”. The condi-
tion was to be suspected in patients with bone expo-
sure in the maxillofacial region following oral surgery. 
Other symptoms such as pain and infection could also 
be present.
In 2006 the American College of Rheumatology (ACR) 
reported that ONJ typically manifests as an intraoral le-
sion with the exposure of white-yellowish bone, some-
times associated to the presence of an intra- or extraoral 
fistula. Likewise in 2006, the American Association of 
Endodontists (AAE) indicated that patients with ONJ 
present at least one of the following characteristics: ul-
ceration of the mucosa with bone exposure in the upper 
maxilla or mandible, pain or swelling, infection and sup-
puration or sensory alterations (18). It is thus clear that 
no agreement has been reached regarding the definition 
of the disease. In the year 2007 the American Associa-
tion of Oral and Maxillofacial Surgeons (AAOMS), in 
its position document on BRONJ, defined the latter as 
the exposure of necrotic bone in the maxillofacial region 
persisting for more than 8 weeks, in patients with cur-
rent or past bisphosphonate therapy and no antecedents 
of radiotherapy of the maxillary region (20). That same 
year, the American Society for Bone and Mineral Re-
search (ASBMR) defined a “confirmed case” of BRONJ 
as the presence of an area of exposed bone in the maxil-
lofacial region failing to heal within 8 weeks after having 
been identified by a health professional in a patient with 
current or past treatment with BPs and no antecedents of 
radiotherapy of the maxillary region. A “suspected case” 
in turn was defined as an area of exposed bone in the 
maxillofacial region, present for less than 8 weeks, and 
identified by a health professional in a patient with the 
same characteristics as described above (21).
In 2008 the Canadian Association of Oral and Maxillo-
facial Surgeons published a consensus document with 
management guidelines referred to BRONJ in which the 
“confirmed case” and “suspected case” definitions in-
troduced by the ASBMR were maintained (22). In 2009 
this same work group published a review on the subject 
in which the same definitions were maintained without 
changes (23). 
The AAOMS, likewise in 2009, published an update 
on the subject without modifying the definition which 
they had proposed two years earlier, and which has been 
maintained up until 2014 (4). However, the AAOMS 
did introduce a new stage (referred to as stage 0), cor-
responding to patients with symptoms but no exposed 
bone. Authors such as Colella et al. in 2009 and Bedog-
ni et al. in 2012, among others, considered that the term 
BRONJ should be redefined in order to include patients 
in stage 0 (24,25). Based on clinical cases published by 
other authors and on the habitual clinical findings, they 
suggested that the definition of BRONJ should include 
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Fig. 1. Article flowchart.
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not only cases with exposed bone but also those with 
necrotic bone in which bone exposure has not yet oc-
curred (24). Furthermore, they considered that the di-
agnosis and classification should be based not only on 
the clinical picture but also on the radiological findings 
(24,25). 
Other investigators such as Bagán et al. in 2009, Jun-
quera and Gallego in 2008, and Mawardi et al. in 2009 
(17,26,27), also suggested that ONJ may manifest in the 
absence of bone exposure, particularly in the early stag-
es, with fistulas, pain and radiographic alterations.
On the other hand, cases have since been published in 
which ONJ has been associated to other antiresorptive 
agents such as denosumab or cancer drugs with antiang-
iogenic effects such as sunitinib, sorafenib, bevacizum-
ab or sirolimus. As a result, some authors have proposed 
other terms such as drug-induced osteonecrosis of the 
jaws or osteonecrosis of the jaws associated to antire-
sorptive agents, in reference to this disorder (10,15). 
In 2014, the AAOMS proposed a change in nomencla-
ture in favor of the term medication-related osteonecro-
sis of the jaws (MRONJ) (14).
Authors Year Country Study variables Type of sample Type of article 
   Concept Diagnosis Classification   
Ruggiero SL, et al. (31) 2006 USA No Yes Yes Clinical experience 
with 141 patients and 
published articles 
Review  
Advisory Task Force on 
BROJ (AAOMS) (20) 
2007 USA Yes Yes Yes Clinical experience Consensus document 
Review 
Khosla S, et al. (21) 2007 USA Yes Yes Yes Published articles Consensus document 
Review 
Bianchi SD, et al. (33) 2007 Italy No No Yes CT study in 42 
patients 
Case series 
McMahon RE, et al. (39) 2007 USA No Yes Yes Clinical experience Letter to the editor 
Khan AA, et al. (22) 2008 Canada Yes Yes Yes Published articles Consensus document 
Systematic review 
Junquera L, et al. (26) 2008 Spain Yes No No 2 cases without bone 
exposure 
Clinical cases 
Silverman SL, et al. (18) 2009 USA Yes Yes Yes Published articles Review 
Khan AA, et al. (23) 2009 Canada Yes Yes No Published articles Consensus document 
Systematic review 
Ruggiero SL, et al. (4) 2009 USA Yes Yes Yes Published articles Consensus document 
Arce K, et al. (35) 2009 USA No Yes No Published articles Review 
Morag Y, et al. (36) 2009 USA No Yes No Published articles Review 
Mawardi H, et al. (27) 2009 USA Yes Yes Yes 5 cases without bone 
exposure 
Clinical cases 
Bagán JV, et al. (17) 2009 Spain No No Yes Clinical experience Letter to the editor 
Colella G, et al. (24) 2009 Italy Yes No No Clinical experience 
and published articles 
Letter to the editor 
Fedele S, et al. (30) 2010 UK No Yes No Study of 332 patients Case series 
Observational study 
Yoneda T, et al. (40) 2010 Japan No Yes Yes Published articles Consensus document 
Systematic review 
Patel S, et al. (10) 2012 USA Yes Yes Yes Published articles Review 
Bagán JV, et al. (41)  
 
2012 Spain No No Yes Study of 126 patients Case series 
Bedogni A, et al. (25) 2012 Italy Yes Yes Yes Clinical experience 
and Published articles 
Letter to the editor 
Ruggiero SL, et al. (14) 2014 USA Yes Yes Yes Published articles Consensus document 
Systematic review 
Schiodt M, et al. (32) 2014 Denmark No No Yes Study of 102 patients Case series 
Bedogni A, et al. (34)  
 
2014 Italy and 
UK 
No Yes Yes Study of 799 patients Retrospective 
multicenter study 
Franco S, et al. (42) 2014 Italy No No Yes Study of 203 patients Retrospective study 
Bagán JV, et al. (37) 2015 Spain No No Yes Study of 43 cases. 
Clinical-CT 
correlation 
Case-control study 
Khan AA, et al. (8) 2015 International Yes Yes Yes Published articles Consensus document 
Systematic review 
 
Table 1. Articles selected for the review and their characteristics.
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In addition to incorporating this change in name of the 
disease, the AAOMS update of 2014 modified its def-
inition. In this regard, a patient is considered to have 
MRONJ if all of the following conditions are met (14):
- Current or past treatment with antiresorptive or an-
tiangiogenic drugs.
- Exposed bone or intra- or extraoral fistulization in the 
maxillofacial region communicating with the bone and 
persisting for more than 8 weeks.
- No history of maxillary radiotherapy or clear maxillary 
metastatic disease.
However, in 2015 the International Task Force on Os-
teonecrosis of the Jaw defined ONJ as follows (8):
- Exposed bone in the maxillofacial region that fails to 
heal in 8 weeks after identification by a health profes-
sional.
- Exposure to an antiresorptive agent.
- No history of craniofacial radiotherapy.
The diagnosis is essentially clinical (28). On the other 
hand, it must be taken into account that there may be 
one or more sites of bone exposure (29). Furthermore, 
these sites may remain asymptomatic for prolonged pe-
riods of time (weeks, months or even years), or clinical 
signs and symptoms may manifest before clinically de-
tectable ONJ develops. Such signs and symptoms con-
sist of pain, bone and/or gingival swelling, erythema, 
suppuration, soft tissue ulceration, intra- or extraoral 
fistular trajectories, tooth mobility, paresthesia and 
even anesthesia, in the absence of any apparent dental/
periodontal cause.
The radiographic findings range from variable radi-
otransparency or radioopacity to the absence of radio-
logical signs. In the absence of bone exposure, these 
findings alone were not regarded as sufficient to diag-
nose BRONJ (21). 
At present, the latest update of the AAOMS correspond-
ing to 2014 (14) considers that the presence of these 
manifestations, even in the absence of bone exposure 
(equivalent to stage 0 of the 2009 classification) is in-
dicative of prodromal BRONJ, and that over time up 
to 50% of these patients will progress towards disease 
stages 1, 2 or 3.
Clinically, the exposure of necrotic bone mostly occurs 
after dentoalveolar surgery (extractions or the place-
ment of dental implants), though it can also be spon-
taneous. The most frequent location is the mandible 
(62-82% of the cases), maxilla (8-18%), or both (up to 
20% of the cases), with a predominance of the molar 
and premolar regions. The exposed bone is generally 
colonized by oral bacteria, giving rise to secondary in-
fections (11,28).
The differential diagnosis of ONJ must be made with 
other conditions such as alveolar osteitis, sinusitis, os-
teomyelitis, periodontitis/gingivitis, periapical disease 
caused by caries, mucositis, osteoradionecrosis, tempo-
romandibular joint disease and certain forms of cement-
bone dysplasia with secondary sequestration phenom-
ena (8,21). Accordingly, the patient case history and the 
clinical examination remain the most sensitive tools for 
diagnosing ONJ (8,30). 
The two most controversial aspects in the diagnosis of 
ONJ since the publication of the first case series have 
been: 1) the diagnosis of ONJ in the absence of bone 
exposure; and 2) the need for radiological or imaging 
confirmation of the diagnosis. These two aspects will 
be examined in greater detail below.
- Diagnosis of ONJ in the absence of exposed bone:
Most authors have accepted the definition of ONJ pro-
posed by the AAOMS in 2007, i.e., an area of exposed 
bone in the maxillofacial region that fails to heal within 
6-8 weeks, in a patient with current or past treatment 
with BPs but without head and neck radiotherapy. How-
ever, as has been commented above, some investigators 
have suggested that ONJ may manifest without bone ex-
posure, particularly in the early stages of the disease. As 
an example, in 2008 Junquera and Gallego (26) described 
two patients with bone sequestration that could be clini-
cally and radiographically classified as corresponding to 
stage 3 ONJ, but without bone exposure. In these cases 
pain and swelling were the main symptoms. The authors 
suggested that there is a variant of ONJ without bone ex-
posure. Based on their clinical experience, Bagán et al. 
in 2009 (17) proposed that the three stages of the 2006 
classification of Ruggiero (31) should include patients 
with intraoral fistulas but no bone exposure, since these 
patients otherwise could not be assigned to any stage.
In 2009, Mawardi et al. (27) described 5 patients sub-
jected to treatment with BPs who developed deep peri-
odontal pockets, tooth mobility or intraoral fistulas with 
or without suppuration, with swelling in some cases, and 
with radiographic alterations (sequestration, sclerosis, 
lack of post-extraction socket healing), but without ex-
posure of necrotic bone. After several months bone ex-
posure occurred in the same zone. The authors regarded 
these cases as corresponding to early stage BAONJ and 
proposed modifying the definition of BONJ to include 
a new category: “suspected BONJ” or stage 0s, since in 
the same way as Bagán et al. (17), they were unable to 
assign the patients to any of the three established ONJ 
stages. 
On the other hand, Fedele et al. in 2010 (30) studied 
332 patients with ONJ and found up to 28.9% of the 
subjects to have clinical manifestations consistent with 
the purported ONJ variant without bone exposure. The 
clinical manifestations in decreasing order of frequency 
were maxillary pain, fistulization, bone expansion and 
gingival swelling. In addition, the symptoms developed 
spontaneously without previous extractions or surgery, 
and in 29.1% of the cases no radiological alterations 
were observed in the panoramic X-ray or computed to-
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mography explorations. Manifest bone exposure was 
seen over time (up to two years of follow-up) in 53.1% of 
these patients. According to the authors, these findings 
may have a significant impact upon the existing epide-
miological data and on the design of future studies. 
According to Patel et al. (10), the absence of exposed 
bone in patients with ONJ can produce a delay in diag-
nosis, prolong the disease and cause it to become refrac-
tory to treatment. They proposed a diagnostic and thera-
peutic approach to cases of ONJ without bone exposure 
based on the symptoms, assessment of the risk factors, 
the radiographic evidence, and patient refractoriness to 
medical treatment. The authors suggested a modifica-
tion of the AAOMS staging or classification system, as 
will be seen below. In 2014, Schiodt et al. (32) indicated 
that the proportion of ONJ without bone exposure may 
be high (29-45% of all cases of ONJ), and that this fact 
could result in potential under reporting of the disease 
in epidemiological studies. The authors evaluated 102 
patients with ONJ, with and without bone exposure, 
and established comparisons between the two groups 
in order to determine whether they corresponded to the 
same disease condition or not. No significant differenc-
es were found between the two groups in terms of the 
demographic data, symptoms, clinical and radiological 
characteristics, histopathological findings or survival. 
As a result, they concluded that both presentations form 
part of the same disease and proposed a new ONJ clas-
sification including patients without bone exposure, as 
will be commented below.
Lastly, as we have seen, the AAOMS update of the year 
2014 (14) modifies the definition of ONJ, with the inclu-
sion of cases of ONJ without bone exposure, though the 
classification does not contemplate such presentations.
- Need for radiological or imaging confirmation of the 
diagnosis:
In 2006, Ruggiero et al. (31), in an article presenting 
guidelines for the diagnosis, staging and treatment of 
ONJ, described the existence of both early and late 
radiographic maxillary changes that could simulate 
other disorders (periapical disease, osteomyelitis, my-
eloma or metastatic disease). In the case of important 
bone involvement, regions with a mottled appearance 
(similar to the pattern seen in osteomyelitis) could be 
found. Likewise, widening of the periodontal ligament 
and bone osteosclerosis could be observed, particularly 
in the region of the hard lamina. However, according to 
these authors, the radiographic changes were not evident 
until important bone alteration had developed. They 
consequently suggested that the panoramic and periapi-
cal X-ray studies might not reveal significant changes 
in the early stages of ONJ. According to Khosla et al. 
(21), in the presence of well established disease, imag-
ing techniques are not needed for diagnostic purposes 
since the presence of exposed bone and other clinical 
signs and symptoms suffice to identify ONJ. Neverthe-
less, they recognized that such techniques may be of 
importance in the early identification of ONJ.
Other authors have used imaging techniques in patients 
of this kind, including computed tomography (CT), 
magnetic resonance imaging (MRI), scintigraphy and 
panoramic and periapical X-rays. As an example, Bi-
anchi et al. in 2007 (33) studied 32 patients with ONJ, 
comparing the alterations found in panoramic X-rays 
versus CT. The latter technique was found to be far 
superior, with the detection of lesions in almost twice 
as many patients. In all cases CT detected structural 
alterations of the trabecular bone and cortical erosion. 
In comparison, the panoramic X-rays failed to detect 
bone sequestration in almost half of the cases. Intense 
periosteal reaction was a common finding, and oroan-
tral communications could also be observed. In 2012, 
Bedogni et al. (25) proposed a new classification of 
ONJ, as will be seen below, based particularly on the 
CT findings. Likewise, in 2014 Bedogni et al. (34) con-
ducted a large retrospective multicenter study of the 
CT findings in 799 patients with ONJ. They found that 
the severity (extension) of the lesions can be identified 
and measured with CT much more accurately than with 
panoramic X-rays or clinical inspection, as proposed by 
some classifications – including that of the AAOMS of 
2009. The authors attempted to correlate the findings 
with the stages proposed by the AAOMS in 2009, and 
concluded that these stages are unable to correctly iden-
tify disease extent or involvement, except in stage 3.
On the other hand, in 2009 Arce et al. (35) conducted 
a review of the findings in ONJ with different imaging 
techniques. According to these authors, the radiographic 
findings are not specific. Intraoral and panoramic X-rays 
may show widening of the lamina dura and of the peri-
odontal ligament, osteolysis, diffuse sclerosis and a lack 
of post-extraction socket healing. The more advanced 
the disease the greater the sclerosis and widening of the 
mandibular canal. Zones of ONJ can be identified in 
quadrants without exposed bone. Computed tomogra-
phy offers a three-dimensional view of the extent of the 
lesion and can detect minor sequestrations. Focal scle-
rosis with a disorganized trabecular pattern is present 
in the early stages of the disease, and neck adenopathies 
and masticatory muscle thickening simulating a tumor 
mass can be detected. Magnetic resonance imaging in 
turn can detect bone marrow and soft tissue involve-
ment, nerve bundles and adenopathies. Bone scintigra-
phy with technetium-99 shows enhanced radionuclide 
uptake between 10-14 days before bone mineral loss 
becomes significant enough to be detectable on X-rays. 
The problem with scintigraphy is its lack of specificity 
and low resolution (35,36). In 2015, Bagán et al. (37) 
analyzed the degree of sclerosis in different ONJ stages 
using CT, and investigated the relationship between the 
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degree of sclerosis, the clinical symptoms and the ex-
tent of the radiotransparencies in 43 cases - establishing 
comparisons with a group of 40 controls without bone 
lesions. The patients with ONJ had more intense sclero-
sis than the controls (p<0.01). Furthermore, the degree 
of sclerosis increased with the clinical stage of ONJ and 
was correlated to the extent of the radiotransparency.
Morphological analysis of the necrotic bone (sequestra-
tions) using micro-CT has been unable to demonstrate 
the existence of unique distinguishing features in pa-
tients with ONJ in different stages (38).
- Classification
In 2006, Ruggiero et al. proposed an ONJ classification 
comprising three stages (31): stage 1 = bone exposure 
but without signs or symptoms of infection; stage 2 = 
bone exposure/necrosis with clinical evidence of infec-
tion; stage 3 = the above manifestations and also altera-
tions such as pathological fractures, extraoral fistulas or 
osteolysis extending to the inferior mandibular margin. 
In 2007 the AAOMS adopted this classification (20), 
though in addition to the group of patients with BRONJ 
(with its three stages), it included another group of pa-
tients comprising individuals at risk. These patients 
were defined as subjects without evident exposed or 
necrotic bone or symptoms, but who have been treated 
with oral or intravenous BPs.
In the year 2009, the AAOMS added a stage 0 to its 
classification, involving alterations (pain, tooth mobil-
ity, fistulas, radiographic changes, etc.) that may have 
been due to treatment with BPs, but without exposed 
bone. The risk of progression towards more advanced 
stages of the disease was not known at that time (4).
Other classifications have also introduced the idea that 
ONJ may be present despite the absence of bone expo-
sure. As an example, McMahon et al. considered that 
an early stage of ONJ with or without symptoms may 
exist in which bone exposure has not yet occurred, since 
the first bone changes are found at marrow level, not 
in cortical bone, and that early detection of this stage 
could improve the patient prognosis and treatment (39). 
They also considered that imaging techniques and his-
tological studies are needed to more precisely catego-
rize the different ONJ stages. The authors proposed 6 
stages (Table 2), but also considered that a stage 0 could 
be useful for identifying patients at risk. Mawardi et al. 
suggested the inclusion of a stage 0s as corresponding 
to “suspected BRONJ”. This stage in turn would com-
prise two subcategories: 0ss in the presence of symp-
toms, and 0sa in the absence of symptoms (27). Bagán 
et al. in turn included fistular lesions in stages 1, 2 and 
3, though without bone exposure, and subdivided stage 
2 into stages 2a and 2b according to whether the con-
dition responded to conservative management or not 
(17). Yoneda et al. accepted the definition of ONJ of the 
AAOMS, but proposed the introduction of four stages 
in accordance with the situation of the disease in Ja-
pan at that time (40). This classification is basically the 
same as that of the AAOMS of 2009, but stage 0 more-
over includes hypoesthesia or anesthesia of the lower 
lip as symptom and the presence of deep periodontal 
pockets as clinical sign (Table 2). Other authors such 
as Bagán et al. in 2012 aimed to validate the classifica-
tion of the AAOMS of 2009 with a retrospective study 
of 126 cases of ONJ due to intravenous and oral BPs, 
comparing both groups and determining whether all the 
cases could be assigned to one or other of the proposed 
stages (41). More cases of ONJ without exposed bone 
were observed in the oral bisphosphonate group, with a 
larger number of advanced cases (stages 2 or 3) in the 
intravenous oral bisphosphonate group. In addition, 6 
cases could not be assigned to any of the stages, for de-
spite the presence of extraoral fistulas and mandibular 
fracture, no exposed bone was identified. The authors 
consequently proposed a new modification of the classi-
fication of Ruggiero et al. (4), with the inclusion in stage 
3 of the term “exposed and necrotic bone or oral fistula 
without exposed bone” (Table 2). Other classification 
proposals are described below:
- Bedogni et al. in 2012 proposed a new classification 
with three stages (25): stage 1 = focal ONJ, stage 2 = 
diffuse ONJ, and 3 = complicated ONJ. In addition to 
clinical findings, this classification includes CT imag-
ing findings and eliminates stage 0. According to these 
authors, the clinical manifestations of pain and suppura-
tion should not be used to differentiate between stages, 
since they only define symptomatic or asymptomatic 
forms of BRONJ within one same stage. This contri-
butes to avoid patient migration from stage 1 to stage 2 
or vice versa (ping-pong effect). These authors funda-
mentally used the CT findings to classify the patients. 
The presence of bone sequestration was not regarded as 
a sign of complex BRONJ (Table 3).
- According to Franco et al. in 2014, most of the exist-
ing classifications are useful from the clinical and di-
agnostic perspective, but none of them offer a surgical 
orientation for the treating surgeon (42). They proposed 
a new dimensional staging system, classifying the le-
sions by size following panoramic X-ray and CT evalu-
ation, with a view to making treatment decisions easier 
(Table 3).
- In 2012, Patel et al. modified the classification of the 
AAOMS of 2009 with the purpose of incorporating pa-
tients without bone exposure and of guiding treatment 
(10). They distinguished between patients with and 
without bone exposure, and in the latter group those 
individuals without symptoms were classified as cor-
responding to stage 1, while those with symptoms were 
assigned to stages 2 or 3 (Table 4). 
- As has been commented, Schiodt et al. in 2014 con-
sidered ONJ with and without bone exposure to corre-
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McMahon et al. (2007) Bagán et al. (2009) 
Stage 1: 
 No exposed/necrotic bone 
 Moderate and intermittent maxillary pain 
 Normal dental/mucosal and radiographic findings 
 Scintigraphy, CT and MRI reveal osteoblastic activity but no 
evident infection  
Stage 2:  
 No exposed/necrotic bone 
 Moderate and constant maxillary pain 
 Normal dental/mucosal findings, but Rx reveal sclerotic changes 
and radiotransparencies 
 Scintigraphy, CT and MRI show alterations 
 No evidence of infection 
Stage 3:  
 No apparent exposed/necrotic bone 
 Constant and severe maxillary pain requiring analgesia 
 Mucosal edema, erythema with severe pain of the bone alveolar 
 Dental Rx, scintigraphy, CT and MRI show alterations 
 There may be infection, though not of dental origin 
Stage 4:  
 <2 cm exposed/necrotic bone without cortical fenestration 
 Important and constant maxillary pain requiring potent analgesia 
 The mucosa surrounding the exposed bone is red and swollen 
 Moderate swelling of the surrounding tissues, without clear 
evidence of infection 
 Dental Rx, scintigraphy, CT and MRI show alterations 
 Dental disease discarded 
Stage 5:  
 >2 cm exposed/necrotic bone with or without cortical fenestration 
 Constant and severe maxillary pain requiring analgesia 
 The mucosa surrounding the exposed bone is red and swollen 
 Mild to moderate swelling of the peripheral tissues with or without 
purulent suppuration 
 Dental Rx, scintigraphy, CT and MRI show alterations 
 Dental disease discarded 
Stage 6:  
 >4 cm exposed/necrotic bone with cortical fenestration and 
infection  
 Important and constant maxillary pain requiring potent analgesia 
 Fetidness. Dental Rx, scintigraphy, CT and MRI show alterations 
 The mucosa surrounding the exposed bone is red and swollen 
 One or more of the following: pathological fracture, extraoral 
fistula, oroantral fistula, osteolysis extending to the inferior 
mandibular margin 
 Dental disease discarded 
  
Stage 1: 
 Presence of exposed necrotic bone or small oral fistula without 
exposure of necrotic bone 
 Asymptomatic 
Stage 2a: 
 Presence of exposed necrotic bone or small oral fistula without 
exposure of necrotic bone 
Patient with symptoms controlled by medical treatment 
Stage 2b: 
 Presence of exposed necrotic bone or small oral fistula without 
exposure of necrotic bone 
 Patient with symptoms not controlled by medical treatment 
Stage 3: 
 Pathological fracture, extraoral fistula, osteolysis extending to the 
inferior mandibular margin 
 
Bagán et al. (2012) 
 
The same stages as in the 2009 classification, but also: 
 
Stage 3: Exposed necrotic bone or oral fistula without exposed 
bone, in patients with pain, infection and one or more of the 
following: radiographic evidence of bone necrosis extending 
beyond the bone alveolar, pathological fracture, extraoral fistula, 
oroantral oronasal communication, osteolysis extending to the 
inferior mandibular margin or sinus floor 
 
 Mawardi et al. (2009) Yoneda et al. (2010) 
 
Proposed modification the classification of the AAOMS of 2007 
(20), introducing a news stage called 0s 
 
Stage 0s: “suspected ONJ” 
 Absence of exposed bone 
 Presence of fistulas, severe tooth mobility, deep periodontal 
pockets, positive radiographic findings 
2 subcategories: 
 Stage 0ss: “suspected” and symptomatic 
 Stage 0sa: “suspected” and asymptomatic 
 
 
Same specifications as the AAOMS in its classification of 2009 (4), 
except:  
 
Stage 0 
 Includes hypoesthesia or anesthesia of the lower lip and/or 
 Deep periodontal pockets 
 
Table 2. Proposals for modification of the ONJ classification of the AAOMS (4,20) by McMahon et al. (39), Bagán et al. (17,41), Mawardi 
et al. (27) and Yoneda et al. (40).
Rx: X-ray, MRI: magnetic resonance imaging, CT: computed tomography, ONJ: osteonecrosis of the jaws.
spond to one same disease entity (32). Accordingly, they 
modified the classification of Patel et al. (10), eliminat-
ing stage 0 and classifying patients both with and with-
out bone exposure in stages 1, 2 or 3 (Table 4).
The classification or staging system currently proposed 
by the AAOMS (14), and which is correlated to thera-
peutic strategies specific of each stage, is as follows:
- At risk: Patients subjected to antiresorptive or antian-
giogenic treatment via the oral or intravenous route, and 
with no symptoms or apparent bone necrosis.
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Table 3. Proposals for the classification of ONJ according to Bedogni et al. (25) and Franco et al. (42).
CT: computed tomography, NSAIDs: nonsteroidal antiinflammatory drugs.
* Radiographic evidence of necrotic bone: irregular areas of hypo- and hypercalcification and/or bone sequestration.
Bedogni et al. (2012) Franco et al. (2014) 
Stage 1  
Focal ONJ 
   Clinical signs and symptoms: bone exposure, sudden 
tooth mobility, no post-extraction socket healing, mucosal 
fistula, inflammation, abscess formation, trismus, 
important mandibular deformity and/or lip hypoesthesia / 
paresthesia 
   CT findings: increased bone density limited to alveolar 
bone (trabecular thickening and/or focal osteosclerosis), 
with or without the following signs: sclerotic and markedly 
thickened hard lamina, persistent socket space and/or 
cortical disruption 
1a. Asymptomatic 
1b. Symptomatic (pain and purulent secretion) 
Stage 2  
Diffuse ONJ 
   Clinical signs and symptoms: the same as in stage 1 
   CT findings: increased bone density extending to the 
basal layer (diffuse osteosclerosis), with or without the 
following signs: inferior dental nerve canal prominence, 
periosteal reaction, sinusitis, bone sequestration and/or 
oroantral fistula 
2a. Asymptomatic 
2b. Symptomatic (pain and purulent secretion) 
Stage 3  
Complicated ONJ 
As in stage 2, with one or more of the following: 
   Clinical signs and symptoms: extraoral fistula, 
mandibular stump displacement, nasal fluid drainage 
   CT findings: osteosclerosis of adjacent bone (zygoma, 
hard palate), pathological mandibular fracture and/or 
osteolysis extending to the sinus floor 
Clinical and radiological findings 
 Stage 0 
     No exposed bone, with nonspecific radiographic 
findings such as osteosclerosis and periosteal 
hyperplasia, and nonspecific symptoms such as pain 
 Stage I 
    Exposed bone and/or radiographic evidence of 
necrotic bone*, or persistent socket space <2 cm in 
greater diameter, with or without pain  
 Stage II 
     Exposed bone and/or radiographic evidence of 
necrotic bone *, between 2-4 cm in major diameter, with 
pain responsive to NSAIDs, and possible abscesses 
 Stage III 
     Exposed bone and/or radiographic evidence of 
necrotic bone *, >4 cm in greater diameter, with intense 
pain that responds or does not respond to NSAIDs, 
abscesses, orocutaneous and/or maxillary sinus 
fistulization, with mandibular nerve involvement 
 
1: osteosclerosis, cortical rupture, osteolysis, subperiosteal bone deposit, thickening of the lamina dura, and widening of 
the periodontal ligament space.
ONJ: osteonecrosis of the jaws; E-ONJ: osteonecrosis of the jaws with exposure; NE-ONJ: osteonecrosis of the jaws with 
no exposure.
Patel et al. (2012) Schiodt et al. (2014) 
Clinical bone 
exposure 
Same stages as 
AAOMS 2009 (4) 
Absence of bone exposure 
Asymptomatic  
Stage 1 NE 
No clinical evidence of infection; there 
may be radiographic findings1 
 
Symptomatic 
Stage 2 NE 
No exposed necrotic bone; clinical 
evidence of infection, presence of 
intraoral fistulas, swelling, pain, 
paresthesia / dysesthesia, and 
radiographic evidence of bone necrosis 
 
Stage 3 NE 
As in stage 2 NE, with one or more of 
the following: 
• Radiographic evidence of bone 
necrosis extending beyond alveolar 
bone 
• Pathological fracture 
• Extraoral fistula 
• Oroantral, oronasal communication 
• Osteolysis extending to the inferior 
mandibular margin or sinus floor 
Bone exposure 
Asymptomatic 
Name: E-ONJ, stage 1 
Bone exposure 
Symptoms of infection 
Name: E-ONJ, stage 2 
 
As in stage 3 of the AAOMS 
Name: E-ONJ, stage 3 
 
No bone exposure 
Asymptomatic 
Name: NE-ONJ, stage 1 
No bone exposure 
Symptoms of infection 
Name: NE-ONJ, stage 2 
 
No bone exposure, with 
necrosis in patients with pain, 
infection, and one or more of 
the following: 
necrotic bone without exposure, 
as evidenced by imaging 
techniques, extending beyond 
alveolar bone, i.e., inferior 
margin or ramus of the 
mandible, maxillary sinus and 
zygoma, pathological fracture, 
extraoral fistula, oroantral or 
oronasal communication, 
osteolysis extending to the 
inferior mandibular margin or 
sinus floor 
Name: NE-ONJ, stage 3 
 
Table 4. Proposals for the staging of ONJ according to Patel et al. (10) and Schiodt et al. (32).
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- Stage 0 (disease variant without bone exposure): No 
clinical evidence of necrotic bone, though with clinical 
findings, radiographic changes and nonspecific symp-
toms.
Among the symptoms:
- Tooth pain in the absence of a dental cause.
- Maxillary bone pain that may irradiate to the region of 
the temporomandibular joint.
- Pain of the maxillary sinuses that may be associated to 
inflammation and thickening of the sinus walls.
- Altered neurosensory function.
Among the clinical findings: 
- Tooth mobility that cannot be explained by periodon-
titis.
- Periapical or periodontal fistulas not associated to pulp 
necrosis secondary to trauma, caries or restorations.
Among the radiographic findings:
- Loss or reabsorption of alveolar bone that cannot be 
explained by periodontitis.
- Changes in trabecular-dense bone pattern, with no for-
mation of new bone in extraction sockets.
- Zones of osteosclerosis in alveolar bone or around the 
basal layer.
- Thickening or opacification of the periodontal liga-
ment (thickening of the lamina dura, sclerosis, and re-
duction of the periodontal ligament space).
- Stage 1: Exposed bone or intra- or extraoral fistuliza-
tion in the maxillofacial region penetrating to the bone, 
in asymptomatic patients without evidence of infection. 
In addition, radiographic findings such as those de-
scribed in stage 0 may be observed in alveolar bone.
- Stage 2: Exposed bone or intra- or extraoral fistuliza-
tion in the maxillofacial region penetrating to the bone, 
with infection evidenced by pain and erythema in the 
region or exposed bone with suppuration. In addition, 
radiographic findings such as those described in stage 0 
may be observed in alveolar bone.
- Stage 3: Exposed bone or intra- or extraoral fistuliza-
tion in the maxillofacial region penetrating to the bone, 
with pain, infection and at least one of the following 
signs:
- Necrotic bone extending beyond the alveolar bone (in-
ferior margin or ramus of the mandible, maxillary sinus 
and zygoma)
- Pathological fracture
- Extraoral fistula
- Oroantral or oronasal communication
- Osteolysis extending to the inferior margin of the 
mandible or sinus floor
As can be seen, no unified classification or staging sys-
tem has yet been established for use by all professionals 
– though most studies are based on the classification of 
the AAOMS. In coincidence with other authors such as 
Bedogni et al. (25), Patel et al. (10) and Schiodt et al. 
(32), we consider that stage 0 should be suppressed and 
that ONJ should be classified into three stages regard-
less of whether there is bone exposure or not. Further-
more, it would be advisable to establish the diagnosis 
not only on the basis of the clinical data but also on the 
findings of the CT scan, since the latter technique of-
fers greater information on the extent and severity of 
the disorder.
Further studies and consensus are therefore needed with 
a view to adopting a single international classification 
allowing the conduction and comparison of epidemio-
logical studies, and contributing to the treatment deci-
sion making process.
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